These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 1962891)
1. Biomarkers and IL-2R in lung cancer. Marino P; Preatoni A; Fonticoli L; Parodi M; Tarolo GL Recenti Prog Med; 1990 Nov; 81(11):702-4. PubMed ID: 1962891 [TBL] [Abstract][Full Text] [Related]
2. Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma. Okada M; Nishio W; Sakamoto T; Uchino K; Yuki T; Nakagawa A; Tsubota N Ann Thorac Surg; 2004 Sep; 78(3):1004-9; discussion 1009-10. PubMed ID: 15337038 [TBL] [Abstract][Full Text] [Related]
3. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351 [TBL] [Abstract][Full Text] [Related]
4. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer. Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660 [TBL] [Abstract][Full Text] [Related]
5. Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer. Tas F; Aydiner A; Topuz E; Yasasever V; Karadeniz A; Saip P J Exp Clin Cancer Res; 2000 Dec; 19(4):477-81. PubMed ID: 11277326 [TBL] [Abstract][Full Text] [Related]
6. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815 [TBL] [Abstract][Full Text] [Related]
7. [Usefulness of carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA), enolase (NSE) and thymidine-kinase (TK) in the monitoring and prognosis of primary carcinoma of the lung]. De Angelis G; De Marinis F; Bigioni D; Migliorino MR; Alma MG; Pigorini F J Nucl Med Allied Sci; 1990; 34(4 Suppl):135-40. PubMed ID: 1965445 [No Abstract] [Full Text] [Related]
8. Evaluation of neuron-specific enolase, tissue polypeptide antigen, and carcinoembryonic antigen as markers for staging and monitoring response to therapy of lung cancer. Spinazzi A; Soresi E; Boffi R; Nonis A; Noseda A; Cobelli S; Scanni A Cancer Detect Prev; 1994; 18(3):209-20. PubMed ID: 8076383 [TBL] [Abstract][Full Text] [Related]
9. Tissue polypeptide antigen in bronchogenic carcinoma. Zatloukal P; Glagolicová A; Linhart M; Sebes A; Hencl P; Mĕricka O Neoplasma; 1993; 40(5):301-3. PubMed ID: 8272159 [TBL] [Abstract][Full Text] [Related]
10. Clinical value of neuron specific enolase and tissue polipeptidic antigen for the management of patients with lung cancer. Spinazzi A; Soresi E; Borghini U; Boffi R; Vigorelli R; Scoccia S J Nucl Med Allied Sci; 1990; 34(4 Suppl):141-5. PubMed ID: 1965446 [No Abstract] [Full Text] [Related]
11. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117 [TBL] [Abstract][Full Text] [Related]
12. [Importance of serum TPA determination in bronchopulmonary cancer. A comparative study of CEA, CA 19.9 and NSE]. Prévost A; Passemard F; Perdu D; Vallerand H; Deschamps F; Lavaud F; Larbre H Rev Mal Respir; 1994; 11(4):379-84. PubMed ID: 7973038 [TBL] [Abstract][Full Text] [Related]
13. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer]. Li R; Li R; Wang Y Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Nisman B; Amir G; Lafair J; Heching N; Lyass O; Peretz T; Barak V Anticancer Res; 1999; 19(4C):3549-52. PubMed ID: 10629651 [TBL] [Abstract][Full Text] [Related]
15. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441 [TBL] [Abstract][Full Text] [Related]
16. Evaluation of Cyfra 21-1 as a marker for lung cancer. Najemnik C; Mohn-Staudner A; Vetter H; Kokron O; Baumgartner G; Scheiner W; Zwick H; Koderhold G; Alth G; Dudczak R Wien Klin Wochenschr; 1996; 108(15):467-72. PubMed ID: 8806188 [TBL] [Abstract][Full Text] [Related]
17. Expression of CEA and trophoblastic cell markers by lung carcinoma in association with histological characteristics and serum marker levels. Slodkowska J; Szturmowicz M; Rudzinski P; Giedronowicz D; Sakowicz A; Androsiuk W; Zakrzewska-Rowinska E Eur J Cancer Prev; 1998 Feb; 7(1):51-60. PubMed ID: 9511851 [TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma. Tomita M; Matsuzaki Y; Edagawa M; Shimizu T; Hara M; Onitsuka T Ann Thorac Cardiovasc Surg; 2004 Apr; 10(2):76-80. PubMed ID: 15209547 [TBL] [Abstract][Full Text] [Related]
19. [The diagnostic values of CA242 combining other tumor markers for lung cancer]. Zhang S; Ma Y; Yang X Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851 [TBL] [Abstract][Full Text] [Related]
20. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer. Buccheri G; Ferrigno D J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]